 |
DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
The clinical study was conducted in Australiafr...
Cryptocurrency is no longer a fringe topic. It is discussed in boardrooms, on trading apps, and at suburban barbecues. Yet ...
Retail has always been a mirror of society. As populations grew, cities formed, technology advanced, and lifestyles chang...
Walk down almost any Australian main street right now—whether it’s a coastal strip, an inner-suburban high street, or a c...
As the summer holidays come to an end, many Aussies will be dreading their return to work and st...
The aftermath of the Bondi terror attacks has brought about a shift in polling for the Albanese ...
Cryptocurrency is no longer a fringe topic. It is discussed in boardrooms, on trading apps, and at...
Mallacoota to Coolangatta — places to stay and things to see There are few journeys that captur...
Fitstop has unveiled a bold new brand look designed to match how its members actually train: strong...
Zenless Zone Zero is currently enjoying its 2.5 version update with new characters like Ye Shunguang...
Life does not stand still. It moves forward relentlessly, but it does not move the same way for ...
Single-origin coffee is expected to increase in popularity among coffee drinkers over the next 12 ...
Retail has always been a mirror of society. As populations grew, cities formed, technology advan...